General descriptionDMT-2′O-TC-rU Phosphoramidite belongs to TC RNA Phosphoramidites. These highly regarded, innovative monomers allow faster and more efficient RNA-based oligonucleotide manufacturing and the potential to build longer RNA oligonucleotides (>100 bases). TC RNA Phosphoramidites streamline the deprotection process resulting in consistently high-quality products, offering time and cost savings.
Features and Benefits- Reduced coupling times
- Improved coupling efficiency
- Single-step downstream process with neat Ethylenediamine (EDA)
- Cleavage and deprotection within two hours at ambient temperature
- Desalting of oligos not required
- Allows for manufacturing of long RNA oligomers
- High yields of final oligonucleotides
- Next-day RNA oligo delivery
Legal InformationFor use with Customer Container sold to end user customers either directly or through distributors.
This product is manufactured and sold under a license from Agilent Technologies under under US Patent No. 8,202,983 and pending U.S. Patent App. Nos. 13/485,5925, 13/531,191, and 13/339,082 and corresponding foreign counterparts, including those issuing from PCT/US08/63342 and PCT/US09/057922 all assigned to Agilent Technologies. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patents to use the product to synthesize Oligonucleotides for buyer′s internal research use only, including commercial purposes. Except as otherwise provided herein, no other license is granted to the buyer weather expressly, by implication, by estoppel or otherwise. Buyer agrees and understands that it is not licensed to use this product to synthesize Oligonucleotides for sale, for diagnostic uses including use in clinical diagnostic settings where the use in conjunction with an individual′s sample generates data provided to an individual or the individual′s caregiver for a free reimbursement, neither can Oligonucleotides synthesized using this product be used for use clinical trials or for other therapeutic purposes. This product is sold pursuant to authorization from Agilent Technologies, Inc. and Agilent Technologies reserves all other rights under these patents.
For use with all sales where the purchaser is required to have its own direct license from Agilent, without limitation, Bulk Quantity Sales, and sales to Oligo Houses.
This product and it uses are covered by under US Patent No. 8,202,983 and pending U.S. Patent App. Nos. 13/485,5925, 13/531,191, and 13/339,082 and corresponding foreign counterparts, including those issuing from PCT/US08/63342 and PCT/US09/057922 all assigned to Agilent Technologies. This product is sold to purchaser pursuant to authorization by Agilent Technologies, Inc. without any rights conferred by seller, based on purchaser′s direct license and authorization to purchase from Agilent Technologies, Inc. No license is granted to the purchaser weather expressly, by implication, by estoppel or otherwise on account of this purchase. Purchase′s rights to use this product are governed solely and expressly by purchaser′s direct license agreement with Agilent.
These products are manufactured and sold under a license from Agilent Technologies under US Patent No. 8,202,983 and pending U.S. Patent App. Nos. 13/485,5925, 13/531,191, and 13/339,082 and corresponding foreign counterparts, including those issuing from PCT/US08/63342 and PCT/US09/057922 all assigned to Agilent Technologies.
These products and its uses are covered by US Patent No. 8,202,983 and pending U.S. Patent App. Nos. 13/485,5925, 13/531,191, and 13/339,082 and corresponding foreign counterparts, including those issuing from PCT/US08/63342 and PCT/US09/057922 all assigned to Agilent Technologies.
